Table 4 Cumulative mortality during follow-up stratified by gender (Life table method)
All-cause mortality % (95% CI) | Cardiovascular mortality % (95% CI) | Cancer mortality % (95% CI) | ||||
|---|---|---|---|---|---|---|
STEMIa | Women | Men | Women | Men | Women | Men |
1 year | 16.2 (14.3–18.4) | 9.2 (8.3–10.1) | 12.9 (11.1–15.0) | 7.6 (6.8–8.5) | 0.7 (0.4–1.4) | 0.6 (0.4–0.9) |
2 years | 20.4 (18.2–22.8) | 10.9 (10.0–12.0) | 15.1 (13.2–17.3) | 8.6 (7.7–9.5) | 2.0 (1.3–3.1) | 1.1 (0.8–1.5) |
3 years | 23.0 (20.7–25.6) | 13.0 (12.0–14.2) | 16.4 (14.4–18.7) | 9.6 (8.7–10.6) | 2.8 (1.9–4.2) | 1.7 (1.3–2.2) |
4 years | 26.4 (23.8–29.2) | 15.3 (14.1–16.6) | 18.4 (16.2–20.9) | 10.5 (9.5–11.6) | 3.6 (2.5–5.1) | 2.4 (1.9–3.0) |
5 years | 28.6 (25.8–31.6) | 17.1 (15.8–18.6) | 19.5 (17.1–22.2) | 11.3 (10.2–12.5) | 3.8 (2.7–5.5) | 3.0 (2.4–3.8) |
NSTEMIb | Women | Men | Women | Men | Women | Men |
1 year | 18.6 (16.9–20.5) | 13.6 (12.5–14.8) | 12.5 (11.0–14.2) | 8.4 (7.5–9.4) | 2.0 (1.4–2.8) | 2.0 (1.6–2.6) |
2 years | 25.2 (23.2–27.3) | 17.3 (16.0–18.6) | 16.2 (14.5–18.0) | 10.6 (9.6–11.7) | 3.5 (2.7–4.6) | 2.8 (2.3–3.5) |
3 years | 31.9 (29.6–34.2) | 21.3 (19.9–22.8) | 20.4 (18.5–22.6) | 12.4 (11.2–13.6) | 4.7 (3.7–6.0) | 4.0 (3.3–4.9) |
4 years | 36.7 (34.3–39.3) | 25.2 (23.6–26.8) | 23.3 (21.1–25.6) | 14.3 (13.0–15.7) | 5.5 (4.3–7.0) | 5.0 (4.2–6.0) |
5 years | 42.0 (39.2–44.9) | 29.3 (27.5–31.2) | 26.2 (23.7–29.0) | 16.4 (14.9–18.0) | 5.7 (4.5–7.3) | 6.3 (5.2–7.5) |